OLIX
Driving drug development through next-generation oligonucleotide technology
London, United Kingdom · Founded 2010 · $213.0M raised
- Headquarters
- London
- Employees
- 51–200
- Founded
- 2010
- Business Model
- B2B
- Website
- olixpharma.com
- Total Funding
- $213.0M
- Last Round
- $213.0M Series AFeb 2026
- Rounds
- 1
About
OliX Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics using its proprietary cp-asiRNA and asiRNA platform technologies. The company is the first Asian organization to advance a self-developed RNAi technology into clinical trials, targeting dermal, ophthalmic, pulmonary, and hepatic diseases. Listed on KOSDAQ (226950), OliX is headquartered in Suwon, South Korea.
Summary
OLIX is a Biotech company based in London, United Kingdom, founded in 2010. It has raised $213.0M in total across 1 round, most recently a $213.0M Series A round in Feb 2026. Investors include octopus investments, LocalGlobe and Entrepreneur First.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Feb 2026
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/olix"><img src="https://indexed.vc/api/badge/company/olix" alt="OLIX on Indexed.vc" width="260" height="76" /></a>